T-AYU- HM Premium Anti-Sickling Medicine for Management of Sickle - PowerPoint PPT Presentation

T-AYU- HM™ Premium Anti-Sickling Medicine for Management of Sickle Cell Anemia. Sicklecare TAYUHM Limited. Improving Quality of Life…

T-AYU- HM™ Premium Composition: Each T-AYU-HM TM Premium tablet (300 mg) contains: 1 Calyx of Mica 25mg 2 Calyx of Iron 12.5mg 3 Terminala chebula 25mg 4 Zingiber officinale 25mg 5 Asparagus racemosus 25mg 6 Punica granatum 12.5mg 7 Myristica fragrans 25 mg 8 Piper longum 37.5 mg 9 Tinospora cordifolia 37.5 mg 10 Leptadinia reticulate 37.5 mg

In-Vitro RBC Sickling ( Emmel’s Test) Results The morphology of Sickle Cells that were incubated under anaerobic conditions in the absence or presence of various 10 mM Vanillin + Ve - Ve Control concentration of T- as standard Control AYU- HM™ Premium compared to 10mM Vanillin (4-Hydroxy-3- methoxybenzaldehyd 50 µg/ml 100 µg/ml e) for 24 hour . 25 µg/ml T-Ayu- HM™ T-Ayu- HM™ Pre T-Ayu- HM™ Pre Pre

In-Vitro RBC Sickling ( Emmel’s Test) Results 10 mM Vanillin + Ve Control - Ve Control as standard 50 µg/ml 100 µg/ml 500 µg/ml 25 µg/ml T-Ayu- HM™ Pre T-Ayu- HM™ Pre T-Ayu- HM™ Pre T-Ayu- HM™ Pre

In-Vitro RBC Sickling ( Emmel’s Test) Results Percent of Sickled cells in presence of T-AYU- HM™ Premium 100 90 80 70 60 % Sickled Cells 50 * 40 * * 30 * 20 * 10 10 mM 25 µg/ml 50 µg/ml 100 µg/ml 500 µg/ml Treatment Control (PBS) Vanillin T-Ayu-HMP T-Ayu-HMP T-Ayu-HMP T-Ayu-HMP 0 control 10 mM 25 µg/ml 50 µg/ml 100 µg/ml 500 µg/ml % Sickle Cells 67.94 24.07 55.22 44.28 39.34 27.41 vanillin HMP HMP HMP HMP (Mean ± ± ± ± ± ± ± stardard 4.47 10.66 4.66 5.77 5.90 8.12 SD) n=5, * p<0.05 as compared to control samples % Inhibition 64.62 18.32 34.51 41.83 59.85 of sickling - ± ± ± ± ± 15.41 10.11 10.21 10.33 11.36 (Mean ± SD) 5

In-Vitro RBC Sickling ( Emmel’s Test) Results 10 mM 25 µg/ml 50 µg/ml 100 µg/ml 500 µg/ml Treatment Control (PBS) Vanillin T-Ayu-HMP T-Ayu-HMP T-Ayu-HMP T-Ayu-HMP % Sickle Cells 67.94 24.07 55.22 44.28 39.34 27.41 (Mean ± ± ± ± ± ± ± 4.47 10.66 4.66 5.77 5.90 8.12 SD) % Inhibition 64.62 18.32 34.51 41.83 59.85 of sickling - ± ± ± ± ± 15.41 10.11 10.21 10.33 11.36 (Mean ± SD)

Oxidative Hemolysis of Sickle Red Blood Cells 100.00 t-BOOH induced Formation of 80.00 Methaemoglobin at 12 Hr 90.00 70.00 Control 80.00 50 ug/ml T-Ayu-HM 60.00 70.00 100 ug/ml T-ayu-HM * Methaemoglobin (%) Percent Haemolysis 50.00 500 ug/ml T-ayu-HM 60.00 40.00 50.00 30.00 40.00 * 20.00 30.00 10.00 20.00 10.00 0.00 0 15 30 45 60 75 90 105 120 0.00 -10.00 Time in Min Control 50 ug/ml T- 100 ug/ml T- 500 ug/ml T- Ayu-HM ayu-HM ayu-HM * indicates significantly different means from the control groups (P<0.05) analyzed by one-way ANOVA followed by Dunnett's comparison test

Membrane Stabilization Activity by Osmotic Fragility Test 120.00 Concentration at Haemolysis 50% 0.59 100.00 0.57 control (PBS) Percentage Haemolysis 50 µg/ml T-Ayu-HM 0.55 80.00 Conc. of NaCl 100 µg/ml T-Ayu-HM 0.53 60.00 500 µg/ml T-Ayu-HM 0.51 10 mM Vanillin 40.00 0.49 0.47 20.00 0.45 control 10 mM 50 µg/ml T- 100 µg/ml 500 µg/ml 0.00 (PBS) Vanillin Ayu-HM T-Ayu-HM T-Ayu-HM 0.00 0.20 0.40 0.60 0.80 1.00 Concentration of NaCl Solution

Stasis Induced Venous Thrombosis in SD Rats 10 Stasis Induced Venous Thrombosis 9 in SD Rats 8 Weight of Throbis (mg) 7 6 * * * 5 4 3 2 1 0 Vehical Control 30 mg/ kg 100 mg/kg 300 mg/kg 500 mg/kg Aspirin T-AYU-HM T-AYU-HM T-AYU-HM n=5, * p<0.05 as compared to control samples using Student’s t test

Conclusion  The ability of T-AYU-HM Premium to normalize the sickle erythrocytes may represent a rational explanation for the use in treating sickle cell anemia.  Sickled RBCs showed a lesser degree of t-BOOH-induced haemolysis in treatment group than control groups and were more resistant to t-BOOH induced hemolysis.  T-AYU-HM Premium causes stabilization of the erythrocytes membrane, reflected in the decrease in osmotic fragility values.  T-Ayu-HM premium significantly shows decrease in thrombus formation.  The present investigation provides evidence to support the claims of the herbomineral formulation for treatment and management of sickle cell anemia

Discussion • Literature survey revealed that herbomineral formulations include various plant extracts and minerals which can be useful in the complications of sickle cell disease. For instance, • Zingiber officinale contains essential oil which possess anti- inflammatory activity (Thomson et al., 2002). Punica Granatum containing brevifolin carboxylic acid, • brevifolin, 7,8-Dihydroxycoumarin 7-Ellagic acid are known to posses anti-oxidant and analgesic activities (Singh et al., 2002, Nawwar et al., 1994, Hussein et al., 1997). Myristica Fragrans shows potent antiplatelet activity, • Antioxidant activity (Duan et al., 2009)

Discussion • Piper longum shows inhibitory activity on platelet aggregation induced by collagen, arachidonic acid, and platelet-activating factor (Park et al., 2007), Terminalia Chebula shows antioxidant properties , contains • polyphenolic compounds like casuarinin, chebulanin, chebulinic acid or 1,6-di-O-galloyl- β -D-glucose (Cheng et al., 2003). Asparagus racemosus shows cytoprotective activity • (Dahanukar et al., 1983) as well as antioxidant activity (Kamat et al., 2000), • Mica Ash useful in anemia, splenomegaly (Desai, 2008), aging and general debility, Iron Ash used in treatment of iron deficiency anaemia • (Pandit et al., 1999).

Application o T-Ayu- HM™ Premium is being used in India by proficient Practitioners for the treatment of sickle cell anemia o Dramatic improvements in the patients conditions were observed with respect to Reduction or freedom from symptoms  Hand & Chest syndrome  Avascular necrosis of femur (AVNF)  Relief from pain  Splenomegaly, jaudice, pallor, backache, abdominal colic, loss of appetite, and headache.  Improvement in hematological parameters  Need for Blood transfusions is also considerably reduced.

Summary of overall relief  It improves quality of life of the patient  It improves general conditions of the patient  It drastically reduces the need for repeated blood transfusions.  It normalizes renal and liver functions  it eliminates the need for splenectomy  it strengthens the cardiac functions  it eliminates chronic fatigue; patients feel more energetic  it prevents kidney damage due to the disease  it prevents formation of gall stones  it improves RBC function  it consists of a balanced mixture of time-tested and safe herbominerals without any side effects  it is manufactured as per FDA standards  Each ingredient is subjected to physical and chemical analysis  Its formulation is subjected to Heavy Metal Microbial testing  Its safety for human use is ascertained by LD50 values

Dosage • 2 tablets daily (Morning and Evening) or as directed by physician for HbSS. • In severe condition 2 tablets twice daily for 120 days for HbSS. • During Crisis 2 tablets twice daily with lifesavers medications. • 1 tablet daily (Morning and Evening) for HbAS. • 2 tablets daily for complications of HbAS. Warning : pregnant women, nursing mothers and children under 5 years have to be prescribed by the attending doctors .

Indications • INDICATIONS AND USAGE: T-AYU- HM ™ Premium tablets are indicated mainly for sickle cell anemia .The product is also useful in other types of anemia • CONTRA INDICATIONS: T-AYU- HM ™ Premium tablets are contraindicated during pregnancy and lactation . • WARNING AGAINST MISUSE: T-AYU- HM ™ Premium is indicated for a specific condition called sickle cell anemia and should be used as per the dosage recommended by the manufacturer; should not be used for conditions not recommended by the manufacturer. • PRECAUTIONS: During the use of T-AYU- HM ™ Premium tablets, patients have to be carefully observed and any untoward reactions to be reported immediately to the attending Physician. Patients have to be carefully and continuously monitored by the attending Physician during the T-AYU- HM ™ Premium therapy. In severe cases of Sickle cell anemia there could be additional need for measures, medications, blood transfusions and even hospitalizations-which should be promptly resorted to. • DOSAGE AND ADMINISTRATION: 2 tablets of 300mg twice a day or as directed by the Physician. • ADVERSE REACTIONS: No specific adverse reaction was reported in patients who have used T-AYU- HM ™ Premium • DRUG ABUSE AND DRUG DEPENDENCE: T-AYU- HM ™ Premium Tablets contain time tested herbal and Ayurvedic ingredients. There is no propensity to cause drug abuse and drug dependence. There is no report of drug abuse or drug dependence. • SYMTOMS OF OVERDOSAGE AND ANTIDOTE: None.